| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Meeting Summary |
1 Memorial Sloan-Kettering Cancer Center, New York, New York;
2 Mayo Clinic, Rochester, Minnesota;
3 Mount Sinai Hospital and Research Institute, Toronto, Ontario, Canada;
4 Yale University School of Medicine, New Haven, Connecticut;
5 Hopital Sainte-Justine, Montreal, Quebec, Canada;
6 University of Nebraska Medical Center, Omaha, Nebraska;
7 St. Jude Children’s Research Hospital, Memphis, Tennessee;
8 Massachusetts General Hospital, Boston, Massachusetts;
9 Indiana University Medical Center, Indianapolis, Indiana;
10 Dana-Farber Cancer Institute and Children’s Hospital, Boston, Massachusetts;
11 Health Sciences Center, University of Connecticut, Farmington, Connecticut;
12 Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland;
13 M. D. Anderson Cancer Center, Houston, Texas;
14 Texas Children’s Cancer Center at Baylor College of Medicine, Houston, Texas;
15 Hospital for Sick Children, Toronto, Ontario, Canada;
16 Stanford University Medical Center, Stanford, California;
17 Children’s Hospital Los Angeles, Los Angeles, California;
18 Johns Hopkins Hospital, Baltimore, Maryland;
19 Georgetown University Medical Center, Washington, DC;
20 College of Veterinary Medicine and Biological Sciences, Colorado State University, Ft. Collins, Colorado;
21 EMMES Corporation, Rockville, Maryland; and
22 Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, Maryland
ABSTRACT
Childhood osteogenic sarcoma (OS) is a rare bone cancer occurring primarily in adolescents. The North American pediatric cooperative groups have performed a series of clinical treatment trials in this disease over the past several decades, and biology studies of tumor tissue have been an important study component. A meeting was held in Bethesda, Maryland on November 29–30, 2001, sponsored by the NIH Office of Rare Diseases, the Children’s Oncology Group, and the National Cancer Institute-Cancer Therapy Evaluation Program with the general objectives: (a) to review the current state of knowledge regarding OS biology; (b) to identify, prioritize, and support the development of biology studies of potential clinical relevance in OS; and (c) to discuss the available tissue resources and the appropriate methods for analysis of OS samples for the conduct of biology studies. This report summarizes the information presented and discussed by the meeting participants.
This article has been cited by other articles:
|
|
 |
|
  A. Spreafico, S. Schenone, T. Serchi, M. Orlandini, A. Angelucci, D. Magrini, G. Bernardini, G. Collodel, A. Di Stefano, C. Tintori, et al. Antiproliferative and proapoptotic activities of new pyrazolo[3,4-d]pyrimidine derivative Src kinase inhibitors in human osteosarcoma cells FASEB J, May 1, 2008; 22(5): 1560 - 1571. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Tolar, A. J. Nauta, M. J. Osborn, A. Panoskaltsis Mortari, R. T. McElmurry, S. Bell, L. Xia, N. Zhou, M. Riddle, T. M. Schroeder, et al. Sarcoma Derived from Cultured Mesenchymal Stem Cells Stem Cells, February 1, 2007; 25(2): 371 - 379. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. Anderson, G. A. Wiseman, L. Erlandson, V. Rodriguez, B. Trotz, S. A. Dubansky, and K. Albritton Gemcitabine Radiosensitization after High-Dose Samarium for Osteoblastic Osteosarcoma Clin. Cancer Res., October 1, 2005; 11(19): 6895 - 6900. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. S. Bruland, H. Hoifodt, G. Saeter, S. Smeland, and O. Fodstad Hematogenous Micrometastases in Osteosarcoma Patients Clin. Cancer Res., July 1, 2005; 11(13): 4666 - 4673. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Laverdiere, B. H. Hoang, R. Yang, R. Sowers, J. Qin, P. A. Meyers, A. G. Huvos, J. H. Healey, and R. Gorlick Messenger RNA Expression Levels of CXCR4 Correlate with Metastatic Behavior and Outcome in Patients with Osteosarcoma Clin. Cancer Res., April 1, 2005; 11(7): 2561 - 2567. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Kitlinska, K. Abe, L. Kuo, J. Pons, M. Yu, L. Li, J. Tilan, L. Everhart, E. W. Lee, Z. Zukowska, et al. Differential Effects of Neuropeptide Y on the Growth and Vascularization of Neural Crest-Derived Tumors Cancer Res., March 1, 2005; 65(5): 1719 - 1728. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P. Sanders, R. Drissi, C. A. Billups, N. C. Daw, M. B. Valentine, and J. S. Dome Telomerase Expression Predicts Unfavorable Outcome in Osteosarcoma J. Clin. Oncol., September 15, 2004; 22(18): 3790 - 3797. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |
